dm+d

388379009

Refrigerated Storage

NeulastaAmgen Ltd

Amgen Ltd
Neulasta
6mg solution for injection in pre-filled syringe and with on-body injector

In the event of an inadvertent temperature excursion the following data may be used:
Neulasta may be exposed to room temperature (not above 30°C) for a maximum single period of up to 72 hours, after which it should be discarded.
The pre-filled syringe with the on-body injector may be exposed at room temperature for no longer than 36 hours prior to filling the on-body injector.
Accidental exposure to freezing temperatures for a single period of less than 24 hours does not adversely affect the stability of Neulasta.

Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
Contact Amgen Ltd in cases where additional stability data is required. Refer to the current BNF for company contact details.

15 March 2021
London MI Service

Lactation Safety Information

pegylated unglycosylated recombinant human granulocyte-colony stimulating factor

pegylated unglycosylated recombinant human granulocyte-colony stimulating factor
Yes
No direct published evidence of safety
Low levels anticipated in milk due to the drug's properties which are unlikley to be absorbed from the infants GI tract
G-CSF is a normal component of breast milk
16 September 2020